4//SEC Filing
Ashe Andrew D. 4
Accession 0000950170-25-050561
CIK 0001840574other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 5:00 PM ET
Size
9.0 KB
Accession
0000950170-25-050561
Insider Transaction Report
Form 4
Ashe Andrew D.
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-04-01+9,000→ 351,509 total - Sale
Common Stock
2025-04-02$4.15/sh−2,681$11,126→ 348,828 total - Exercise/Conversion
Restricted Stock Units
2025-04-01−9,000→ 27,000 total→ Common Stock (9,000 underlying)
Footnotes (3)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
- [F2]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 30, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
- [F3]On February 14, 2024, the reporting person was granted 36,000 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2025 and the remainder vesting in equal annual installments until April 1, 2028.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001573163
Filing Metadata
- Form type
- 4
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 5:00 PM ET
- Size
- 9.0 KB